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Chronic graft-versus-host disease (cGVHD) is an immune-mediated disorder and is the major long-term
complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The oral mucosa, including
the salivary glands, is affected in the majority of patients with cGVHD; however, at present there is only a
limited understanding of disease pathobiology. In this study, we performed a quantitative proteomic analysis
of saliva pooled from patients with and without oral cGVHDdcGVHD(þ) and cGVHD(), respectivelydusing
isobaric tags for relative and absolute quantiﬁcation labeling, followed by tandem mass spectrometry. Among
249 salivary proteins identiﬁed by tandem mass spectrometry, 82 exhibited altered expression in the oral
cGVHD(þ) group compared with the cGVHD() group. Many of the identiﬁed proteins function in innate or
acquired immunity, or are associated with tissue maintenance functions, such as proteolysis or the cyto-
skeleton. Using ELISA immunoassays, we further conﬁrmed that 2 of these proteins, IL-1 receptor antagonist
and cystatin B, showed decreased expression in patients with active oral cGVHD (P < .003). Receiver operating
curve characteristic analysis revealed that these 2 markers were able to distinguish oral cGVHD with a
sensitivity of 85% and speciﬁcity of 60%, and showed slightly better discrimination in newly diagnosed pa-
tients evaluated within 12 months of allo-HSCT (sensitivity, 92%; speciﬁcity 73%). In addition to identifying
novel potential salivary cGVHD biomarkers, our study demonstrates that there is coordinated regulation of
protein families involved in inﬂammation, antimicrobial defense, and tissue protection in oral cGVHD that
also may reﬂect changes in salivary gland function and damage to the oral mucosa.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a life-
threatening immunologic condition that occurs following
allogeneic hematopoietic stem cell transplantation (allo-
HSCT), affecting 30% to 70% of patients who survive more
than 3 months [1-3]. Its presentation may be progressive,
arising from acute GVHD that merges into cGVHD, or de
novo, with no previous acute GVHD. cGVHD has been char-
acterized as both an alloimmune and autoimmune disease,
affecting multiple tissues of the transplant recipient,
including the skin, oral mucosa, liver, and eyes [1]. It involves
different, predominantly T cellemediated immunologic
mechanisms, including donor-derived alloreactive T lym-
phocytes, autoreactive T lymphocytes, and dysregulated
expression of inﬂammatory mediators [4]. Although T lym-
phocytes are the primary mediators of cGVHD, a role for B
lymphocytes in cGVHD is suggested by the presence of serum
autoantibodies and B cell markers, such as B cell activating
factor, as well as recent promising results obtained using
drugs that target B cell surface antigens [5].edgments on page 1054.
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14.03.031The oral mucosa is affected in the majority (51% to 63%) of
cGVHD patients at the initial diagnosis and is the second
most commonly involved tissue after the skin [2]. Common
manifestations of oral cGVHD include tissue atrophy, ery-
thema, edema, lichenoid changes, and mucoceles [6,7].
Damage to salivary glands frequently leads to xerostomia,
which, together with reduced salivary immunoglobulin
production, increases the risk of oral infections [8]. In more
severely affected patients, signiﬁcant pain associated with
oral lesions and sclerodermatous changes can lead to
ﬁbrosis, which causes trismus (limited mouth opening) and
compromised oral function. In addition to the signiﬁcant
morbidity and mortality associated with cGVHD, the disease
can mimic other autoimmune or inﬂammatory conditions,
such as scleroderma and lichen planus [1,9]. Thus, bio-
markers that can distinguish cGVHD from other clinically
similar immune conditions would be very useful diagnostic
tools.
Given that the oral mucosa and salivary glands are major
target organs of numerous human diseases, salivary prote-
omics is an appropriate methodology for the molecular
proﬁling of oral-associated diseases, including cGVHD, Sjög-
ren’s syndrome, periodontitis, and oral cancer (reviewed in
[10]). Saliva represents an ideal starting point for identifying
potential cGVHD biomarkers, because changes in the salivary
proteome should be directly associated with the localizedTransplantation.
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serum, which in principle reduces the time and cost required
for the analysis of mass spectrometry (MS) data [11]. Whole
saliva is composed of ﬂuid including proteins produced by
major andminor salivary glands, as well as both secreted and
nonsecreted proteins produced by mucosal, periodontal, and
immune cells that reside in the mouth. Several previous
studies have usedMS and immunoassay-based approaches to
identify potential oral GVHD markers [7,12,13]; however, to
date there is little consensus as to whether any of the iden-
tiﬁed salivary proteins might be useful for diagnosis or pre-
dicting patient outcomes.
In an effort to obtain a global proﬁle of proteomic alter-
ations occurring in oral cGVHD, we used a quantitative MS
approach to identify salivary proteins displaying altered
expression in patients with active oral cGVHD. We identiﬁed
82 salivary proteins that showed quantitative changes in
expression in oral cGVHD, and further validated 2 of these
proteins using ELISA immunoassays.
MATERIALS AND METHODS
Study Population
Clinical details and demographics of the allo-HSCT study population are
presented in Table 1. Patients who had undergone allo-HSCT procedure at
the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
were recruited for this study through the Long-Term Follow-Up Program,
either at the anniversary visit or during a later appointment required forTable 1
Clinical Characteristics of Allo-HSCT Recipients Used in Proteomic Studies
Characteristic Phase 1
Oral cGVHD(þ)
(n ¼ 10)
Oral cGVHD()
(n ¼ 10)
Age, yr, median (range) 55 (38-67) 56.5 (21-63)
Sex, n (%)
Male 5 (50) 5 (50)
Female 5 (50) 5 (50)
Original disease, n (%)
AML 5 (50) 3 (30)
ALL 0 2 (20)
CML 0 2 (20)
Myeloﬁbrosis 2 (20) 0
NHL 1 (10) 2 (20)
Other 2 (20) 1 (10)
Conditioning regimen, n (%)
Radiotherapy/chemotherapy 6 (60) 6 (60)
Chemotherapy only 4 (40) 4 (40)
Type of donor, n (%)
Related 4 (40) 4 (40)
Unrelated 6 (60) 5 (50)
Haploidentical 0 1 (10)
Cell source, n (%)
Bone marrow 0 6 (60)
PBSCs 10 (100) 3 (30)
Cord Blood 0 1 (10)
Type of transplant, n (%)
Myeloablative 5 (50) 4 (40)
Nonmyeloablative 5 (50) 6 (60)
GVHD prophylaxis, n (%)
MTX þ tacrolimus 3 (30) 4 (40)
MMF þ tacrolimus 2 (20) 1 (10)
CSP þ MMF 3 (30) 5 (50)
CSP þ MTX 1 (10) 0
Other 1 (10) 0
Acute GVHD, n (%)y 7 (70) 9 (90)
Months of post-transplantation
saliva collection, mean (range)
16.1 (6.7-34.5) 23.3 (12-62.7)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia;
cyclosporin; MMF, mycophenolate plus Cellcept and Myfortic; MTX, methotrexate
* Age and saliva collection data were compared between oral cGVHD(þ) and ora
characteristics were compared using a 2-tailed exact chi-square test.
y Indicates number of patients in whom aGVHD was seen in 1 or more tissues.ongoing treatment of cGVHD [14]. At these appointments, a comprehensive
assessment of patients was completed by an attending oncologist, including
a computed tomography scan, complete physical examination including
evaluation of cGVHD status, and proﬁling of serum proteins and electrolytes
as needed. Global cGVHD severity was scored according to the National
Institutes of Health global severity scale [15] on a scale of 0 to 4 for each of 7
organs (mouth, skin, eye, gastrointestinal tract, liver, lung, and joints/fascia;
with asymptomatic involvement scored as 0, to severe as 4). All allo-HSCT
recipients were in remission at the time of saliva collection.
Oral examinations to assess oral cGVHD were performed at the Oral
Medicine clinic at Seattle Cancer Care Alliance. Diagnosis of oral cGVHD was
based on mucosal changes, including atrophy of the mucosal surfaces, with
loss of normal surface keratinization of the gingiva and dorsal tongue; er-
ythema, especially vascular inﬂammation; hyperkeratinization, including
lichenoid and plaque-like changes; mucoceles, especially on the soft palate
and lower labial mucosa; ulcers; and erythema of the parotid duct [6]. The
protocol was approved by the Institutional Review Board of the Fred
Hutchinson Cancer Research Center, and all participants provided informed
consent.
For phase 1 of the study, an additional 20 healthy adults were recruited
for salivary proteomic analysis through the University of Washington School
of Dentistry. These individuals were divided into 2 groups, middle-aged to
elderly adults (n ¼ 10), with an average age of 58 years (range, 50 to
68 years), and young adults (n ¼ 10), with an average age of 27 years (range,
21 to 34 years). Each group contained an equal number of males and fe-
males. The protocol was approved by the University of Washington’s Insti-
tutional Review Board.Saliva Collection and Processing
Unstimulated whole saliva was collected from each consented human
subject essentially as described previously [16]. The subject was asked toPhase 2
P Value* Oral cGVHD(þ)
(n ¼ 36)
Oral cGVHD()
(n ¼ 10)
P Value*
.91 42 (25-76) 38.5 (31-68) .51
1.0 23 (64) 3 (30) .077
13 (36) 7 (70)
1.0 9 (25) 2 (20) .77
4 (11) 2 (20)
2 (5.5) 1 (10)
3 (8.3) 0
3 (8.3) 1 (10)
15 (41.6) 4 (40)
1.0 23 (64) 3 (30) .77
13 (36) 7 (70)
1.0 16 (44.4) 5 (50) 1.0
20 (55.6) 5 (50)
0 0
.003 8 (22.2) 1 (10) .13
27 (75) 7 (70)
1 (2.8) 2 (20)
.67
1.0 29 (80.6) 7 (70)
7 (19.4) 3 (30)
.76 18 (50) 4 (40) .62
1 (2.8) 0
5 (13.9) 1 (10)
3 (8.4) 0
9 (25) 5 (50)
.58 20 (55.5) 6 (60) 1.0
.26 40.8 (10-121.6) 24.4 (12-80.9) .16
CML, chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; CSP,
.
l cGVHD() patient groups using a 2-tailed Student t test. The other patient
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collection. Immediately before collection, the subject rinsed his or her
mouth with water. Whole saliva was collected over a 15-minute period
directly into a sterile 50-mL vial that was kept on ice throughout. If a subject
had difﬁculty producing adequate saliva, a funnel was inserted on top of the
vial to facilitate collection.
After collection, saliva was centrifuged at 17,000  g for 15 minutes at
4C to remove bacteria andmucosal cells. The supernatant was removed and
treated with Protease Inhibitor Cocktail (50 mL/1 mL of whole saliva; Sigma-
Aldrich, St. Louis, MO) tominimize protein degradation. Saliva samples were
divided into 0.5-mL aliquots and stored at 80C.
Labeling of Saliva Samples
Proteins from 4 different pools of saliva, obtained from the oral
cGVHD(þ) and oral cGVHD() groups collected in phase I (Table 1), as well
as from 2 groups of healthy adults (to allow identiﬁcation of salivary pro-
teins that showed altered expression as a result of normal physiological
aging), were ﬁrst trypsinized and labeled with isobaric Tags for Relative and
Absolute Quantiﬁcation (iTRAQ) chemical tags. Protein samples (240 g) from
each pooled saliva sample were prepared in an 8 M urea buffer after tri-
chloroacetic acid precipitation and then reduced by incubation with 5 mM
triﬂuoroacetic acid for 1 hour at 37C; cysteine residues were blocked by
incubation for 10 minutes in 10 mM methyl methane at room temperature.
Proteins were digested by the addition of 5 mL of sequencing-grade trypsin
(Promega, Madison, WI) and incubation at 37C for 2 hours, followed by a
second incubation with an additional 5 mL of trypsin at 37C for 16 hours.
The trypsin-digested samples were labeled with iTRAQ reagents (Applied
Biosystems, Foster City, CA) according to the manufacturer’s protocol, as
described previously [17]. Each pooled saliva sample was labeled with a
different iTRAQ label, and then the 4 saliva samples were combined to create
a single sample for MS analysis.
Glycoprotein Enrichment and Analysis
Glycoproteins/peptides were separately isolated from the iTRAQ-labeled
saliva pools as described previously [18]. After trypsin digestion and iTRAQ
labeling, the samples were desalted through a C18 column (Waters, Milford,
MA) with 0.1% triﬂuoroacetic acid to remove uncoupled iTRAQ reagent. The
samples were then oxidized with sodium periodate (ﬁnal concentration
12.5 mM) by incubation at room temperature for 1 hour. After a further
desalting step on a C18 column, the samples were dried, and the ﬂow-
through fraction was saved for tandem MS analysis. The freeze-dried sam-
ples were coupled to hydrazide resin (Bio-Rad, Hercules, CA) in 0.1 M
sodium acetate and 0.15 MNaCl (pH 5.5). After the 24-hour binding step, the
supernatant was collected, and the hydrazine resinwaswashed 3 times with
1.5 M NaCl, 3 times with 80% acetonitrile, 3 times with 100% methanol, 3
times with deionized water, and ﬁnally 3 times with 0.1 M NH4HCO3 (pH
8.3). The supernatants (nonglycopeptides) were saved for tandem MS
analysis. The hydrazine resinwas then treated with Peptide:N-Glycosidase F
(PNGase F) (New England Biolabs, Beverly, MA) dissolved in 0.1 M NH4HCO3
(pH 8.3) for a total of 48 hours. The supernatant containing the released
glycopeptides was collected, and the resin was rinsed 3 times in 0.05 M
NH4HCO3 buffer and then twice with 80% acetonitrile, followed by centri-
fugation at 3000  g for 5 minutes after each wash. The glycopeptide-
containing supernatants were then processed for tandem MS as described
below.
Tandem MS Analysis and Protein Identiﬁcation
Quantitative tandem MS analysis was performed using the 4800 Pro-
teomics Analyzer with TOF/TOF Optics (AB SCIEX, Framingham,MA). TheMS
reﬂector positive ion mode was used, with automated acquisition in the
800- to 4000-m/z range with 1000 shots per spectrum. A maximum of 15
peaks were selected per spot, with a minimum signal-to-noise ratio of 50
and a cluster area of 500. Approximately 48,872 precursors were subjected
to tandem MS in the entire study. Proteins were identiﬁed using the
MASCOT algorithm (Matrix Science, Boston, MA) and searched against a
human International Protein Index (IPI) database (version 3.84) with Pro-
teinPilot version 3.0 and the Paragon method [19]. The raw peptide identi-
ﬁcation results from the Paragon algorithm searches were further processed
with the Pro Group algorithm within the ProteinPilot software before ﬁnal
display. Protein quantiﬁcation was achieved by averaging iTRAQ ratios of all
the peptides identiﬁed within each polypeptide. Normalization using a
Gaussian distribution with median of 1 (when comparing all peptides be-
tween the control and experimental groups) was performed after iTRAQ
ratios were calculated. A protein was considered signiﬁcantly increased in
expression if the iTRAQ ratio [eg, oral cGVHD(þ)/oral cGVHD()] was >1.6
and signiﬁcantly decreased if this ratio was <0.65 [20].
To exclude salivary proteins that might be markers of normal physio-
logical aging, all proteins showing a signiﬁcantly increased iTRAQ ratio inboth the allo-HSCT patient population [ie, oral cGVHD(þ)/oral cGVHD()]
and during normal aging (ie, elderly adults/young adults) were removed
from the ﬁnal MS dataset. The same exclusion criteria were applied to
proteins that showed a signiﬁcantly decreased iTRAQ ratio in both groups.
Protein Function and Pathway Analysis
Gene Ontology analysis was performed using the online program
Database for Annotation, Visualization, and Integrated Discovery (DAVID),
version 6.7 [21]. Proteins up-regulated and down-regulated in the oral
cGVHD(þ) group relative to the cGVHD() group were classiﬁed according
to biological process, cellular component, molecular function, and cellular
pathway.
ELISA Assays
Proteins were chosen for validation as potential oral cGVHD biomarkers
based on a signiﬁcant iTRAQ ratio (iTRAQ ratio <0.65 or >1.6) [20] and the
availability of a high-quality ELISA assay. IL-1 receptor antagonist (IL-1ra)
and cystatin B (CSTB, or Steﬁn B) were measured using ELISA assay kits (R&D
Systems, Minneapolis, MN). Dilutions of saliva typically used in immuno-
assays were 1:1000 for IL-1Ra and 1:400 for CSTB. ELISA data were analyzed
using parametric 4-PL curve ﬁtting software (ReaderFit; Hitachi Solutions
America, San Bruno, CA) to determine concentrations of samples based on a
standard curve. The R2 values for our ELISA standard curves were typically in
the range of 0.98 to 0.995. Protein assays were carried out using the BCA
Protein Assay Kit (Pierce Biotechnology, Rockford, IL), and ELISA immuno-
assay data were normalized to protein concentration, per milligram of
salivary protein.
Statistical Analysis
Protein levels determined using ELISA immunoassays were compared
between groups using the Mann-Whitney U test, and the correlation be-
tween marker protein levels was described by the Spearman rank correla-
tion. Protein expression data were analyzed using Sigmaplot (Systat
Software, San Jose, CA) or SPSS version 19 (IBM, Armonk, NY). A receiver
operating characteristic (ROC) curve analysis was used to assess the diag-
nostic potential of selected proteins, including ROC curves for single and
combined protein markers, using Sigmaplot or SPSS. Differences were
considered statistically signiﬁcant at P < .05. Patient characteristics were
compared using the Student t test and exact chi-square test.
RESULTS
Patient Characteristics
Table 1 summarizes the clinical characteristics of the allo-
HSCT recipients. The patients in the oral cGVHD(þ) and oral
cGVHD() groups with saliva samples collected in phase I
were used for the MS studies, whereas patients with samples
collected in both phase I and phase II were used for the
validation studies using immunoassays. The 2 patient groups
in each phase of the study were generally well matched in
terms of age, sex, original disease, and type of transplant
received. A history of acute GVHDwas seen in 63% of the oral
cGVHD(þ) group, compared with 75% of the oral cGVHD()
group (Table 1). In the oral cGVHD(þ) group, the National
Institutes of Health global severity score ranged from 1 to 10
(mean, 3.5; n ¼ 42 patients), and the number of involved
tissues varied from 1 to 4. After the oral mucosa (100%
affected), skin was the most commonly involved site (52%;
n ¼ 22), followed by the eye (45%; n ¼ 19). The vast majority
(83%) of patients in the oral cGVHD(þ) group had disease
involvement at 2 or more sites.
The meanwhole saliva ﬂow rate was slightly lower in the
cGVHD(þ) group compared with the cGVHD() group and
healthy adult controls, but the difference was not statistically
signiﬁcant (Table 2). Overall, patients in the cGVHD(þ) group
were at an average of 36 months post-HSCT at the time of
saliva collection, compared with an average of 31.7 months
for the oral cGVHD() group (P ¼ .65).
Oral cGVHD Proteome
For MS studies (phase 1), the 4 pooled saliva samples
collected from 40 subjects, split into 2 groups of allo-HSCT
Table 2
Salivary Flow Rates of Allo-HSCT Recipients and Healthy Adult Subjects
Study Group No. of
Subjects
Salivary Flow Rate,
mL/min  1 SD
P Value*
Oral cGVHD(þ) 37 0.37 mL/min  0.23 —
Oral cGVHD() 15 0.415 mL/min  0.16 .49
Elderly adults 10 0.415 mL/min  0.05 .53
Young adults 10 0.45 mL/min  0.1 .30
* Comparing the salivary ﬂow rate of each group of subjects to the oral
cGVHD(þ) group, using a 2-tailed Student t test.
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with a different iTRAQ label and then combined and sub-
jected to tandem MS simultaneously. Out of a total of 249
proteins identiﬁed by tandem MS, 82 proteins were signiﬁ-
cantly changed in expression as a result of oral cGVHD, basedTable 3
Salivary Proteins Up-Regulated in Patients with Oral cGVHD
Accession Protein/Gene Name
IPI00790899 55-kDa protein
IPI00300786 Alpha-amylase 1/AMY1A
IPI00847635 Alpha-1-antichymotrypsin isoform 1/SERPINA3
IPI00552432 Basic salivary proline-rich protein 2/PRB2
IPI00019482 Basic salivary proline-rich protein 4/PRB4
IPI00296654 BPI fold-containing family B member 2/BPIFB2
IPI00032293 Cystatin C/CST3
IPI00002851 Cystatin D/CST5
IPI00032294 Cystatin S/CST4z
IPI00305477 Cystatin SN/CST1z
IPI00220327 Cytokeratin-1/KTR1
IPI00021304 Cytokeratin-2e/KRT2
IPI00300725 Cytokeratin-6A/KRT6A
IPI00019359 Cytokeratin-9/KRT9
IPI00009865 Cytokeratin-10/KRT10
IPI00873806 FAM3B isoform A/FAM3Bz
IPI00784293 Golgi membrane protein 1/GOLM1
IPI00853068 Hemoglobin alpha-2/HBA2
IPI00654755 Hemoglobin subunit beta/HBB
IPI00012024 Histatin-1/HTN1
IPI00012026 Histatin-3/HTN3
IPI00387120 Ig kappa chain V-IV region Len
IPI00854743 IgG heavy chain variable region/ENSP00000375034
IPI00304808 Kallikrein-1/KLK1
IPI00383717 Kallikrein, intron-containing (fragment)
IPI00025023 Lactoperoxidase/LPO
IPI00848342 Lactotransferrin precursor/LTFz
IPI00019038 Lysozyme C/LYZ
IPI00009123 Nucleobindin-2/NUCB2
IPI00646304 Peptidyl-prolyl cis-trans isomerase B/PPIB
IPI00004573 Polymeric immunoglobulin receptor/PIGR
IPI00748533 PRB3 protein/PRB3
IPI00022974 Prolactin-inducible protein/PIP
IPI00377025 Proline-rich protein HaeIII subfamily 1/PRH1; PRH2
IPI00856018 Proline-rich protein 4/PRR4
IPI00023011 Proline-rich protein 3/SMR3B
IPI00008580 Secretory leukocyte protease inhibitor/SLPI
IPI00642739 TIMP1 metallopeptidase inhibitor 1/TIMP1
IPI00299729 Transcobalamin-1/TCN1
IPI00414884 Uncharacterized protein C4orf40/C4orf40
IPI00374315 UPF0762 protein C6orf58/C6orf58
IPI00006705 Uteroglobin/SCGB1A1
IPI00784119 V-ATPase subunit S1/ATP6AP1
IPI00166729 Zinc-alpha-2-glycoprotein/AZGP1
ND indicates not determined.
* iTRAQ ratios of healthy elderly adult/young adult saliva sample.
y Proteins (n ¼ 15) in the adult control saliva dataset that show the opposite tre
dataset.
z Proteins obtained from the glycoprotein dataset. In some cases, the same proteon the iTRAQ data comparing saliva samples from the
cGVHD(þ) and cGVHD() groups. Forty-four of those 82
proteins were signiﬁcantly up-regulated in the oral
cGVHD(þ) group (Table 3), whereas the other 38were down-
regulated (Table 4). Of the 82 salivary proteins altered in the
oral cGVHD(þ) group, 13 were identiﬁed as glycoproteins by
hydrazine-afﬁnity chromatography and tandemMS (Tables 3
and 4). Proteins involved in innate and acquired immunity
and inﬂammation, as well as oral (tooth) protection and
various housekeeping functions, were prominently repre-
sented in the MS dataset (see below).
Additional analysis of the iTRAQ dataset obtained from
the 2 healthy adult groups revealed that 29 proteins (35%)
identiﬁed as part of the oral cGVHD proteome showed the
opposite trend in expression, based on iTRAQ data, during
normal physiological aging (Tables 3 and 4). Speciﬁcally, 15Peptides,
n (% Coverage)
iTRAQ Ratio
[GVHD(þ)/GVHD()]
iTRAQ Ratio
(Adult Control)*
10 (19.7) 1.58 0.94
889 (83.4) 4.88 0.65
8 (16.3) 2.38 1.23
12 (29.7) 12.3 1.3
12 (29.7) 10.72 1.14
17 (22.7) 2.36 0.50y
11 (45.9) 2.1 0.9
23 (43) 2.85 1.14
ND 2.94 0.72
127 (67.4) 3.76 0.86
ND 1.92 1.03
136 (66.7) 37.5 1.13
25 (34.9) 3.26 1.44
10 (14.9) 2.25 1.19
5 (8.7) 10.73 0.80
5 (8) 1.87 0.9
23 (29.5) 2.26 1.48
ND 3.79 0.89
7 (17) 2.03 0.64y
10 (53.5) 11.0 0.23y
13 (55.1) 15.0 0.35y
18 (36.8) 6.82 0.33y
0.56 (27.5) 5.53 0.395y
ND 2.29 1.02
2 (13.5) 2.10 0.99
0.93 (23.3) 1.67 1.23
6 (22.2) 1.53 1.09
20 (19.5) 3.05 0.47y
ND 1.53 0.96
61 (48.3) 3.16 0.39y
16 (37.8) 7.85 0.14y
12 (23.3) 1.94 0.87
5 (20.4) 1.67 0.70
87 (43.9) 1.91 0.26y
18 (28.5) 2.20 0.94
29 (65.8) 13.0 0.41y
190 (79.5) 12.76 0.43y
7 (26.1) 5.40 0.74
72 (67.1) 10.37 0.84
1 (9.1) 3.1 0.48y
2 (14.7) 2.06 0.64y
5 (10.6) 9.91 0.82
5 (23.3) 2.29 0.96
11 (24.6) 1.65 0.45y
1.1 (11) 1.61 1.08
ND 2.04 0.76
61 (52) 21.57 0.69
nd in relative expression compared with the oral cGVHD(þ)/oral cGVHD()
in was identiﬁed in both the glycoprotein (z) and nonglycoprotein samples.
Table 4
Salivary Proteins Down-Regulated in Patients with Oral cGVHD
Accession No. Protein/Gene Name Peptides,
n (% Coverage)
iTRAQ Ratio
[GVHD(þ)/GVHD()]
iTRAQ Ratio
(Adult Control)*
IPI00021263 14-3-3 protein zeta-delta/YWHAZ 1.43 (28.6) 0.50 2.0y
IPI00747533 56-kDa protein/PGD 8 (16.2) 0.52 1.23
IPI00021439 Actin, cytoplasmic 1/ACTB ND (60.8) 0.44 2.09y
IPI00465248 Alpha-enolase/ENO1 19 (35.3) 0.60 1.5y
IPI00419215 Alpha-2-macroglobulin-like protein 1/A2ML1z ND 0.56 1.46
ND (7.7) 0.66 0.95
IPI00654709 Aldehyde dehydrogenase/ALDH3A1 3 (5.7) 0.59 1.30
IPI00304557 BPI fold-containing family A member 2 (SPLUNC2)/BPIFA2z 42 (63.5) 0.47 1.42
0.60 0.69
IPI00027486 Carcinoembryonic antigen/CEACAM5z ND 0.47 1.78y
IPI00292532 Cathelicidin antimicrobial peptide/CAMP 1 (5.2) 0.58 2.08y
IPI00021828 Cystatin-B/CST6 31 (79.6) 0.45 1.34
IPI00021885 Fibrinogen alpha chain/FGA 7 (6.4) 0.45 1.02
IPI00298497 Fibrinogen beta chain/FGB 9 (20) 0.37 1.37
IPI00219757 Glutathione S-transferase P/GSTP1 7 (43.3) 0.63 1.90y
IPI00478493 Haptoglobin-related protein/HRPz ND 0.49 1.66y
IPI00641737 Haptoglobin/HPz ND 0.49 1.47
IPI00003111 Ig kappa chain V-I region AU/LOC652694 0.97 (28.8) 0.49 0.86
IPI00430847 IGKC protein/IGKC 0.88 (55.1) 0.44 0.86
IPI00829626 IGL@ protein 23 (36.5) 0.37 0.70
IPI00479708 Ig mu chain C region/IGHMz ND (9) 0.56 2.06
24 (27.7) 0.19 1.74y
IPI00175024 IL-1 receptor antagonist protein/IL1RN 9 (49.7) 0.40 1.24
IPI00219077 Leukotriene A-4 hydrolase, isoform 1/LTA4H 1.10 (5.2) 0.57 1.54y
IPI00004310 Ly6/PLAUR domain-containing 3/LYPD3z ND 0.56 1.57y
IPI00027409 Myeloblastin/PRTN3 6 (25.8) 0.64 1.81y
IPI00236556 Myeloperoxidase, proteinase 3/MPOz ND 0.54 0.96
8 (7.3) 0.55 0.72
IPI00005721 Neutrophil defensin 1/DEFA1 1.34 (19.2) 0.57 1.71y
IPI00027769 Neutrophil elastase/ELANE 2 (2.6) 0.61 1.405
IPI00169383 Phosphoglycerate kinase 1/PGK1 8 (23.7) 0.61 1.48
IPI00010796 Protein disulﬁde-isomerase/P4HB 15 (30.3) 0.45 1.45
IPI00479186 Pyruvate kinase isozymes M1, M2/PKM2 9 (16) 0.60 1.41
IPI00816799 Rheumatoid factor D5 light chain (fragment) 7 (35.6) 0.41 1.04
IPI00027462 S100A9/MRP14 45 (80.7) 0.48 3.07y
IPI00216298 Thioredoxin/TXN 11 (51.4) 0.57 1.085
IPI00300376 Transglutaminase-3/TGM3 8 (11.1) 0.48 1.41
IPI00788802 Transkelotase variant (fragment)/TKT 1.07 (8.8) 0.62 1.13
IPI00426051 Uncharacterized protein DKFZp686C15213 11 (20) 0.55 1.02
IPI00423462 Uncharacterized protein DKFZp686K18196 88 (34.7) 0.50 1.07
IPI00877792 Fibrinogen gamma chain/FGGz ND 0.38 1.64y
1.04 (11) 0.32 1.08
IPI00887678 Uncharacterized protein/LOC654188 6 (21.5) 0.60 1.27
* iTRAQ ratios of healthy elderly adult/young adult saliva sample.
y Proteins (n ¼ 14) in the adult control saliva dataset that show the opposite trend in relative expression compared with the oral cGVHD(þ)/oral cGVHD()
dataset.
z Proteins obtained from the glycoprotein dataset. In some cases, the same protein was identiﬁed in both the glycoprotein (z) and nonglycoprotein samples.
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samples were down-regulated during normal aging
(comparing young adults and middle-aged adults), and 14
proteins that were down-regulated in oral cGVHD(þ) saliva
samples were up-regulated with normal physiological aging.
Functional Classiﬁcation and Pathway Analysis
To functionally classify the salivary proteins that dis-
played altered expression in the oral cGVHD(þ) group, we
performed Gene Ontology analysis using the DAVID bioin-
formatics knowledge base [21]. The majority (33 of 59; 56%)
of the cGVHD-altered proteins identiﬁed by this database
were either secreted or known to have an extracellular
function (Supplementary Figure 1A). Many of these proteins
also had a protein-binding activity, either as proteinase in-
hibitors or as enzymes, such as proteases and hydrolases.
To identify speciﬁc trends in the expression data, we
grouped proteins belonging to the same gene family or that
were functionally similar, and determined a mean iTRAQ
value (Supplementary Figure 1B). Among the proteinsup-regulated in the oral cGVHD(þ) group were numerous
proteins that function in innate immunity or oral tissue
protection, including salivary cystatins, histatins, and proline-
rich proteins (Supplementary Figure 1B). Cytokeratins were
also abundant in oral cGVHD(þ) saliva. Among the down-
regulated proteins were several proteinases, including
neutrophil elastase and myeloperoxidase, as well as several
glycolytic enzymes and antiapoptotic factors (Supplementary
Figure 1B). The results show that proteins within a family or
that have a common function, such as proteolysis or anti-
microbial activity, were frequently coregulated in the oral
cGVHD(þ) group.
Examination of IL-1ra and CSTB as Potential Oral cGVHD
Biomarkers
Figure 1 summarizes the salivary expression of IL-1ra and
CSTB in the oral cGVHD(þ) and oral cGVHD() groups,
normalized to salivary protein concentration. Levels of IL-1ra
and CSTB were both reduced by w2.3-fold in the oral
cGVHD(þ) group compared to the oral cGVHD() group
0500
1000
1500
2000
2500
3000
IL-1ra
Oral cGVHD(+)         Oral cGVHD(-)
P = .002
0
500
1000
1500
2000
2500
P = .001
CSTB
ng
/m
g 
pr
ot
ei
n
Oral cGVHD(+)         Oral cGVHD(-)
Figure 1. IL-1ra and CSTB are down-regulated in oral cGVHD. The levels of salivary IL-1Ra and CSTB were measured in individual patients in the oral cGVHD(þ) and
oral cGVHD() groups by ELISA, and the results displayed as boxplots. The top and bottom of each box indicate the 75th percentile and 25th percentile, respectively.
The line inside each box indicates the median concentration. The top and the bottom ends of the whiskers represent 90th and 10th percentiles. Outliers are shown as
dots. Signiﬁcance levels were calculated using the Mann-Whitney U test. The median values (from left to right) are as follows: IL-1ra: 244.7 ng/mL for oral cGVHD(þ)
and 567.5 ng/mL for oral cGVHD(); CSTB: 345.8 ng/mL for oral cGVHD(þ) and 796.5 ng/mL for oral cGVHD().
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rank correlation between the 2 proteins was 0.69 (P < .001).
We performed ROC curve analysis to further assess
marker performance. The area under the curve for the oral
cGVHD(þ) group was 0.76 for the 2 markers, with a sensi-
tivity of 85% and speciﬁcity of 60% (Table 5). Patients with
oral cGVHD who were examined within 12 months of allo-
HSCT exhibited slightly better sensitivity (92%) and speci-
ﬁcity (73%) with the 2-marker panel, although the number of
patients was relatively small (n ¼ 24) (Table 5).
To date, all proteins measured by immunoassay, including
IL-1ra and CSTB, have shown the same upward or downward
trend in expression as predicted from the iTRAQ analysis of
pooled saliva samples. These ﬁndings support the use of the
iTRAQ/tandem MS approach for proteomic discovery [17,20].
DISCUSSION
cGVHD remains the primary long-term complication of
allo-HSCT and is a major hurdle to the more widespread use
of allo-HSCT worldwide [2,22]. Chronic inﬂammation, tissue
damage, and apoptosis are central aspects of cGVHD patho-
biology; this tissue damage can be mediated directly by
inﬁltrating T lymphocytes and indirectly by proinﬂammatory
cytokines, including IL-1, TNF-a, and IL-17 released by
various types of immune cells [4,8,23]. In accordance with
this disease model, we identiﬁed numerous proteins asso-
ciated with oral cGVHD that function in inﬂammation and/or
innate immunity [24], as well as proteins involved in normal
cellular maintenance and survival (Tables 3 and 4). The
presence of elevated cytokeratins in oral cGVHD(þ) salivaTable 5
Receiver Operating Curve Characteristics for Oral cGVHD Biomarkers
Marker AUC P Value* Sensitivity, % Speciﬁcity, %
All allo-HSCT recipientsy
L-1ra 0.74 .002 87 60
CSTB 0.765 .001 78 80
IL-1ra þ CSTB 0.76 .001 85 60
Newly diagnosed patientsz
IL-1ra 0.76 .034 85 64
CSTB 0.78 .019 92 64
IL-1ra þ CSTB 0.8 .014 92 73
AUC indicates area under the curve.
* Tests whether the AUC value is signiﬁcantly different from 0.5.
y Comparison was between 46 patients with oral cGVHD(þ) and 20 with
oral cGVHD().
z Comparison was between 13 patients with oral cGVHD(þ) and 11 with
oral cGVHD() studied at 12 months post-transplantation.samples (Supplementary Figure 1B) is likely a biochemical
marker of mucosal tissue damage and cell death [9]. Alter-
ations in innate and acquired immunity is closely associated
with the pathobiology of cGVHD in different target organs
[13,25,26] and is clinically relevant to cGVHD-associated
mortality, which in most cases results from serious bacte-
rial and/or fungal infections [1].
Saliva is largely a product of the parotid and subman-
dibular salivary glands, and its protein and nonprotein
composition is a reﬂection of both local and systemic
(serum-derived) sources. In cGVHD, damage to salivary
glands is rapid and often severe, affecting both overall saliva
production and composition [27-29]. Patients typically have
higher concentrations of metal ions such as sodium and
magnesium, as well as albumin, IgG, and total protein
[30,31]. Salivary ﬂow rates are generally reduced [27],
although some recent studies have found no difference in
ﬂow rates between patients with and those without oral
cGVHD ([13] and this study). Damage to salivary glands likely
varies depending on the intensity of conditioning (including
whether or not radiotherapy is used) and accompanying
levels of T lymphocytes and proinﬂammatory cytokines.
We examined the expression of 2 proteins selected from
the MS dataset and conﬁrmed in an expanded patient pop-
ulation that IL-1ra and CSTB had signiﬁcantly altered
expression in association with oral cGVHD (Figure 1). IL-1ra
is a protein that binds to the IL-1 receptor and blocks IL-1
signaling. It is produced in both secreted (soluble) and
intracellular forms by immune cells, keratinocytes, and
several other cell types [32]. Altered expression of IL-1Ra is
associated with numerous chronic inﬂammatory diseases,
including rheumatoid arthritis. Donor and recipient IL-1Ra
genotypes have been shown to affect the incidence and/or
severity of acute GVHD and cGVHD, respectively [33,34]. An
altered balance between IL-1 and IL-1ra has been proposed
as a factor governing the severity of several inﬂammatory
conditions, including rheumatoid arthritis and Crohn disease
[35]. Salivary IL-1Ra levels were markedly lower in the oral
cGVHD(þ) group compared with the oral cGVHD() group
(Figure 1), which might favor excessive IL-1 signaling in the
oral mucosa [7]. CSTB, a protease inhibitor and member of
the cystatin family, functions as an inhibitor of cathepsins L,
H, and B and may regulate cathepsin-mediated apoptosis in
neuronal cells [36]. Along with its action as a protease in-
hibitor, CSTB has been proposed to have other functions,
including the regulation of glycolysis and inhibition of the
INF-b pathway in association with HIV infection [37]. One of
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M2, an enzyme that is down-regulated in oral cGVHD(þ)
saliva (Table 4). Thus, the markedly diminished expression of
CSTB in oral cGVHD could affect multiple cellular functions,
including cathepsin protease activity and INF signaling. CSTB
is present in human saliva primarily in several S-modiﬁed
forms; how these modiﬁcations might inﬂuence function is
unclear, however [38].
An important focus of current GVHD research is to
develop biomarker panels that eventually might serve as
diagnostic tools and to inform patient prognosis and treat-
ment strategies [39]. To date, a number of candidate cGVHD
biomarkers have been reported, including serum B cell
activating factor [25], serumMHC class Ierelated chain A and
its antibodies [40], serum IL-15 [41], serum CXCL9 [42], and
salivary lactotransferrin and lactoperoxidase [13]. Those
studies differ in terms of the bioﬂuid examined (serum or
saliva), type of population studied (pediatric or adult), and
proteomic analysis methodology. While there is considerable
overlap between the serum and salivary proteome [11], it is
likely that serum and salivary biomarkers for cGVHD will be
distinct and will measure disease activity in different tissues.
In the case of IL-1ra and CSTB, additional studies with both
independent sets of cGVHD patients, as well as longitudinal
studies, are needed to determine their potential utility as oral
biomarkers of cGVHD. Another recent report indicated that
salivary IL-1ra levels were reduced in oral cGVHD patients,
suggesting that this protein indeed may have utility as an
oral cGVHD biomarker [43].
In summary, we have used a proteomic approach to
describe the alterations in salivary protein expression that
occur in patients with oral cGVHD, and have identiﬁed 2
potential biomarkers for this disease. This study provides
new insight into the inﬂammatory and anti-inﬂammatory
pathways that may be involved in the persistence of this
chronic inﬂammatory disease, and adds new proteins that
might serve as research or diagnostic tools in the study of
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